GFM
BEAM icon

GF Fund Management’s Beam Therapeutics BEAM Stock Holding History

GF Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.1K Sell
2,159
-120
-5% -$3.62K ﹤0.01% 358
2026
Q1 		$54.3K Buy
2,279
+285
+14% +$7.91K ﹤0.01% 388
2025
Q4 		$55.3K Sell
1,994
-182
-8% -$4.64K ﹤0.01% 399
2025
Q3 		$52.8K Buy
2,176
+56
+3% +$1.11K ﹤0.01% 390
2025
Q2 		$36.1K Hold
2,120
– – ﹤0.01% 447
2025
Q1 		$41.4K Buy
2,120
+381
+22% +$9.98K ﹤0.01% 439
2024
Q4 		$43.1K Buy
+1,739
New +$44.4K ﹤0.01% 401

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

GF Fund Management's BEAM Position: Q2 2026 in Review

GF Fund Management reduced its Beam Therapeutics (BEAM) stake by 5.3% in Q2 2026, selling an estimated $3.62K and leaving 2,159 shares worth $74.1K. The position accounts for ﹤0.01% of the portfolio, ranked #358.

GF Fund Management first reported a position in BEAM in Q4 2024 and has held it in 7 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • GF Fund Management held 2,159 shares of Beam Therapeutics worth $74.1K as of Q2 2026.
  • GF Fund Management sold 120 Beam Therapeutics shares in Q2 2026, an estimated $3.62K.
  • Beam Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #358 holding.
  • GF Fund Management first reported a position in Beam Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.